2018 American Transplant Congress
Transplanting Kidneys from HCV-Infected Donors into HCV-Negative Recipients: Longer-Term and Extended Results of the THINKER Trial
1University of Pennsylvania, Philadelphia; 2Gift of Life, Philadelphia.
Background: In 2016, 800 kidneys from HCV+ deceased donors were discarded. Short-term (6-month) data from the first 10 subjects in the THINKER-1 trial (NCT02743897; funder:…2018 American Transplant Congress
Single-Center Experience with Sofosbuvir-Based HCV Treatment after Kidney Transplantation
Nephrology and Kidney Transplant Department, ISCMPA, Porto Alegre, Brazil.
Chronic hepatitis C (HCV) infection is an important clinical challenge after kidney transplantation. This is the initial report of a single-center experience with sofosbuvir-based HCV…2018 American Transplant Congress
Hepatitis C Recurrence after Liver Transplant: A Comparison of Antibody Induction versus No Antibody Induction
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Hepatitis C virus (HCV) recurrence after orthotopic liver transplant (OLT) is universal and exhibits accelerated progression to cirrhosis. Progression can be mitigated by new…2018 American Transplant Congress
Use of HCV Ab+/NAT- Donors in HCV Naïve Renal Transplant Recipients
1Univeristy of Cincinnati Medical Center, Cincinnati, OH; 2The Christ Hospital, Cincinnati, OH.
The continued organ shortage in renal transplantation (RT) has stimulated use of organs from increased-risk donors to expand the donor pool. The rate of denovo…2018 American Transplant Congress
Clinical Outcomes of Kidney Transplant Recipients Infected with Hepatitis C Virus and Treated with Direct-Acting Antiviral Therapy
Introduction:Hepatitis C virus (HCV) infection has negative impact on patient and graft survival in kidney transplant recipients. In the past, treatment of HCV infection post…2018 American Transplant Congress
Disparity in Access to Kidney Allograft Offers among HIV+ Transplant Candidates
Background: Despite having a demonstrated survival benefit with kidney transplantation, patients with chronic viral infections, such as HCV or HIV, face many barriers to transplantation,…2018 American Transplant Congress
Timing of Treatment for Chronic Hepatitis C Infection in Patients with End-Stage Renal Disease Awaiting Transplantation
BackgroundIt is unclear whether patients with chronic hepatitis C virus (HCV) infection and end-stage renal disease (ESRD) should be treated for HCV before transplant or…2018 American Transplant Congress
Clinical and Pathological Findings in Hepatitis C Positive Renal Transplant Recipients Following Alemtuzumab Induction
University of Maryland Medical Center, Baltimore.
BackgroundHistorically, renal transplant recipients (RTRs) with chronic hepatitis C (HCV) have worse long-term outcomes. Induction with alemtuzumab (ALM) in HCV positive RTRs has been postulated…2018 American Transplant Congress
Excellent Outcomes for HCV-Viremic Recipients of Simultaneous Liver-Kidney Transplant in the Direct Anti-Viral Era
Piedmont Transplant Institute, Piedmont Healthcare, Atlanta, GA.
Before the era of direct anti-viral agents (DAAs), outcomes for HCV-viremic recipients of simultaneous liver kidney transplant (SLKT) were inferior to HCV-negative recipients. PURPOSE: To…2018 American Transplant Congress
Diagnostic Accuracy of Non-Invasive Test of Hepatic Fibrosis in Liver Transplant Recipients
Background & Aims: Hepatic fibrosis is an important predictor of liver- and non-liver related outcomes in patients with chronic liver disease (CLD) and liver transplantation…
American Transplant Congress abstracts